Mary Elizabeth Hartnett,
MD
Languages Spoken: English
Mary Elizabeth Hartnett, MD, holds the Calvin S. and JeNeal N. Hatch Presidential Endowed Chair in Ophthalmology and Visual Sciences and is a Distinguished Professor at the University of Utah. She is an adjunct professor at the University of Utah departments of Neurobiology, Anatomy, and Pediatrics. Dr. Hartnett is the founder and director of Pediatric Retina at the John A. Moran Eye Center and principal investigator of the Retinal Angiogenesis Laboratory.
As director of Moran's Pediatric Retina Center, Dr. Hartnett is one of a few pediatric retina specialists internationally trained to diagnose and treat pediatric retina disorders, which disrupt the healthy development of the light-sensitive tissue at the back of the eye. There are dozens of conditions that cause retinal blindness in infants and children, but most are rare. She is one of only a handful of pediatric retina specialists in the United States offering complete care for these challenging conditions. She also practices as a vitreoretinal surgeon, providing treatment to patients throughout the Mountain West. She performs surgery at both the Moran Eye Center and Primary Children's Hospital.
Her mission is to deliver the best possible care and education while conducting critical research to make future advances in pediatric retina care.
She created the first-ever academic textbook on the subject, Pediatric Retina, currently in the second edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally. She is a director of the Advances in Pediatric Retina meeting held every two years, most recently in 2019 at the University of Utah, serving to provide training in established and new methods to manage pediatric retinal conditions and to incite collaborations in research in pediatric retina.
Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology.
Dr. Hartnett's prolific publication record includes 214 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, and as a mentor for the ARVO Leadership Development Program. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the Journal of the American Association for Pediatric Ophthalmology and Strabismus. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of Association for Research in Vision and Ophthalmology (FARVO).
She received her BS-MD from Rensselaer Polytechnic Institute and Albany Medical College, as part of a six-year biomedical program, and performed retinal fellowships in adult and pediatric retina at Schepens Retina Associates. Dr. Hartnett completed post-doctoral training at Harvard University/Schepens Eye Research Institute in retinal cell and molecular biology in the laboratory of Patricia D'Amore and then in GTPases and molecular cell biology at the University of North Carolina with Keith Burridge. She has served as Retinal Director for the residencies at State University of New York at Buffalo and Louisiana State University.
Clinical Locations
801-581-2352
Board Certification and Academic Information
| Academic Departments | Ophthalmology/Visual Sciences
-
Professor Pediatrics - Adjunct Professor |
| Academic Divisions | Pediatric Administration |
| Board Certification | American Board of Ophthalmology |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.7/ 5
Care provider's explanation of condition/problem
4.6/ 5
Care provider's effort to include me in decisions
4.6/ 5
Wait time at clinic
4.0/ 5
Care provider's concern for questions & worries
4.6/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 21, 2021
MORAN EYE CENTER
They didn't describe pros and cons with me but I've seen improvement with what they have been doing so I'm thrilled
UofU Patient
September 19, 2021
MORAN EYE CENTER
I haven't seen my provider since the beginning of July. I was told by a nurse (at least I think she was a nurse) that I did not need a shot because there was no change in my scans. There was no Information given concerning the issues I had listed with the other nurse, there was no information about other options available. You change my insurance hundreds of dollars every time I walk through the door. I think I should at the least get 5 minutes of my provider's time to address my concerns.
UofU Patient
September 19, 2021
MORAN EYE CENTER
Very painful experience
UofU Patient
August 21, 2021
MORAN EYE CENTER
Have been coming here for about 4 years.
UofU Patient
August 07, 2021
MORAN EYE CENTER
There were no "issues" to discuss- my condition is stable, and it was not necessary to explain options or further treatment.
UofU Patient
July 25, 2021
MORAN EYE CENTER
I was very impressed, my physician is a retina specialist and noticed another abnormality and referred me to follow up about glaucoma and my bloodwork with my primary physician. Dr. Hartnett clearly showed astute care for the whole patient.
UofU Patient
July 19, 2021
MORAN EYE CENTER
I was treated very kind and all my questions were explained. I was able to see the test results and have them explained to me.
UofU Patient
June 20, 2021
MORAN EYE CENTER
since the doctor herself never came into my exam room I can only assume she didn't do her job as far as I was concerned.
UofU Patient
May 22, 2021
MORAN EYE CENTER
she explained everything
UofU Patient
May 17, 2021
MORAN EYE CENTER
Very professional
UofU Patient
May 09, 2021
MORAN EYE CENTER
i expressed concern fir worsening depression around my vision and i was given a new prescription and told to try that. There is not really concern for the patient overall just the eyes. No referral to counselor or psychiatrist or anything like that. I am left to deal with it in my own.
UofU Patient
May 03, 2021
MORAN EYE CENTER
Everything clearly explained and questions answered
UofU Patient
April 14, 2021
MORAN EYE CENTER
Dr Hartnett was great but she didn't give me a definitive diagnosis and recommended seeing me again in 4 to 6 weeks, which is a very long time to wait to hear what's wrong with you.
UofU Patient
April 10, 2021
MORAN EYE CENTER
okay
UofU Patient
April 03, 2021
MORAN EYE CENTER
Doctor Hartnett is one of the best doctor I see.
UofU Patient
February 28, 2021
MORAN EYE CENTER
good
UofU Patient
February 17, 2021
MORAN EYE CENTER
dr's are always amazing and so is the staff
UofU Patient
January 03, 2021
MORAN EYE CENTER
Great visit!
UofU Patient
December 07, 2020
MORAN EYE CENTER
Dr. Heartnett clealy explained and showed via scans the condition of my retina and the change since my last visit. She also shares her evaluation of the condition and her opinion on treatment. She clearly explains risk/benefits of potential treatments without being prescriptive. I never feel rushed or discounted when I have an exam.
UofU Patient
November 30, 2020
MORAN EYE CENTER
Good
UofU Patient
November 30, 2020
MORAN EYE CENTER
Dr. Hartnett is incredible. She has a terrific bedside manner and really cares about [NAME REMOVED]. She spent a few minutes reviewing previous procedures and talking about the planned surgery. She then followed up after anesthesia was administered to notify us of the surgical item necessary for [NAME REMOVED] healing. We were involved 100% of the time.
UofU Patient
November 28, 2020
MORAN EYE CENTER
Dr Hartnett is amazing! This has been a very difficult journey after our son's eye injury and she has taken such good care of him! It has definitely relieved the stress.
UofU Patient
October 11, 2020
MORAN EYE CENTER
excellent experience. friendly, well informed ,
UofU Patient
October 06, 2020
MORAN EYE CENTER
Just a very long wait. Inexcusable. And no one every told me anything about waits or what was going on.
UofU Patient
October 04, 2020
MORAN EYE CENTER
excellent
UofU Patient
August 10, 2020
MORAN EYE CENTER
always very professional
UofU Patient
June 26, 2020
MORAN EYE CENTER
Dr. Hartnett is monitoring an ongoing condition with my left retina. She clearly explains her observations regarding progression, and next steps (continue to monitor, possible surgery). She takes time to answer questions and answers clearly and completely.
UofU Patient
June 24, 2020
MORAN EYE CENTER
good
UofU Patient
June 09, 2020
MORAN EYE CENTER
Dr. Hartnett has always been most professional. My only issue is time management and waiting time. This visit was excellent.
Mary Elizabeth Hartnett, MD, holds the Calvin S. and JeNeal N. Hatch Presidential Endowed Chair in Ophthalmology and Visual Sciences and is a Distinguished Professor at the University of Utah. She is an adjunct professor at the University of Utah departments of Neurobiology, Anatomy, and Pediatrics. Dr. Hartnett is the founder and director of Pediatric Retina at the John A. Moran Eye Center and principal investigator of the Retinal Angiogenesis Laboratory.
As director of Moran's Pediatric Retina Center, Dr. Hartnett is one of a few pediatric retina specialists internationally trained to diagnose and treat pediatric retina disorders, which disrupt the healthy development of the light-sensitive tissue at the back of the eye. There are dozens of conditions that cause retinal blindness in infants and children, but most are rare. She is one of only a handful of pediatric retina specialists in the United States offering complete care for these challenging conditions. She also practices as a vitreoretinal surgeon, providing treatment to patients throughout the Mountain West. She performs surgery at both the Moran Eye Center and Primary Children's Hospital.
Her mission is to deliver the best possible care and education while conducting critical research to make future advances in pediatric retina care.
She created the first-ever academic textbook on the subject, Pediatric Retina, currently in the second edition, which has proven to be an invaluable resource for residents and ophthalmologists internationally. She is a director of the Advances in Pediatric Retina meeting held every two years, most recently in 2019 at the University of Utah, serving to provide training in established and new methods to manage pediatric retinal conditions and to incite collaborations in research in pediatric retina.
Dr. Hartnett has received numerous awards, including the Weisenfeld Award, the highest award for clinician-scientists given by the Association for Research in Vision and Ophthalmology (ARVO), in 2018. She received the 2019 Paul Kayser/Retina Research Foundation Global Award, the Macula Society’s 2016 Paul Henkind Award and its 2019 Arnall Patz Medal, and the 2021 Suzanne Veronneau-Troutman Award, the most prestigious award from Women in Ophthalmology.
Dr. Hartnett's prolific publication record includes 214 articles in peer-reviewed journals and over 40 book chapters. She has delivered numerous national and international invited lectures. Her long list of professional committee work includes serving as chair of the Publications Committee of ARVO, and as a mentor for the ARVO Leadership Development Program. She reviews manuscripts for more than 20 eye and science journals and serves on the editorial boards of PlosOne, Molecular Vision, and the Journal of the American Association for Pediatric Ophthalmology and Strabismus. Dr. Hartnett is a Fellow of the American College of Surgeons (FACS) and a Silver and Gold Fellow of Association for Research in Vision and Ophthalmology (FARVO).
She received her BS-MD from Rensselaer Polytechnic Institute and Albany Medical College, as part of a six-year biomedical program, and performed retinal fellowships in adult and pediatric retina at Schepens Retina Associates. Dr. Hartnett completed post-doctoral training at Harvard University/Schepens Eye Research Institute in retinal cell and molecular biology in the laboratory of Patricia D'Amore and then in GTPases and molecular cell biology at the University of North Carolina with Keith Burridge. She has served as Retinal Director for the residencies at State University of New York at Buffalo and Louisiana State University.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Ophthalmology/Visual Sciences
-
Professor Pediatrics - Adjunct Professor |
| Academic Divisions | Pediatric Administration |
| Board Certification | American Board of Ophthalmology |
Education History
| Post Graduate Training | Children’s Hospital and Schepens Eye Research Institute, Harvard University Molecular and Cell Biology Postgraduate Studies, 2000 |
| Fellowship | Schepens Retina Associates, Massachusetts Eye and Ear Infirmary, Harvard Medical School Vitreoretinal Medical/Surgical Training in Pediatric Retina Fellow, 1990 |
| Research Fellow | Harvard University Senior Research Ophthalmology Fellow Research Fellow, 1990 |
| Fellowship | Schepens Retina Associates Chief Fellow, 1989 |
| Fellowship | Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates Vitreoretinal Medical/Surgical Training in Adult Retina Fellow, 1989 |
| Research Fellow | Schepens Eye Research Institute, Harvard Medical School Research Fellow, 1989 |
| Residency | University Hospitals of Cleveland, VA Medical Center Ophthalmology Resident, 1987 |
| Internship | University Hospitals of Cleveland Intern, 1984 |
| Professional Medical | Albany Medical College Medicine (Combined BS/MD program) M.D., 1983 |
| Undergraduate | Rensselaer Polytechnic Institute Biology (Combined BS/MD program) B.S., 1982 |
| Other Training | St. Peter's Hospital Hospice Team Training , 1980 |
Selected Publications - Journal Articles
Journal Article
- Wang H, Ramshekar A, Kunz E, Hartnett ME (2021). 7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment. Angiogenesis, 24(3), 583-595.
- Ramshekar A, Wang H, Kunz E, Pappas C, Hageman GS, Chaqour B, Sacks DB, Hartnett ME (2021). Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. FASEB J, 35(7), e21642.
- Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget-Faysse M, Behar-Cohen F, Hartnett ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM (2021). Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res, 100973.
- Pivodic A, Johansson H, Smith LEH, Hrd AL, Lfqvist C, Yoder BA, Hartnett ME, Wu C, Brnder MC, Lagrze WA, Stahl A, Al-Hawasi A, Larsson E, Lundgren P, Grnse L, Sunnqvist B, Tornqvist K, Wallin A, Holmstrm G, Albertsson-Wikland K, Nilsson S, Hellstrm A (2021). Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity. Br J Ophthalmol.
- Stagg BC, Stein JD, Medeiros FA, Wirostko B, Crandall A, Hartnett ME, Cummins M, Morris A, Hess R, Kawamoto K (2020). Special Commentary: Using Clinical Decision Support Systems to Bring Predictive Models to the Glaucoma Clinic. Ophthalmol Glaucoma, 4(1), 5-9.
- Hicks PM, Haaland B, Feehan M, Crandall AS, Pettey JH, Nuttall E, Self W, Hartnett ME, Bernstein P, Vitale A, Shakoor A, Shulman JP, Sieminski SF, Kim I, Owen LA, Murtaugh MA, Noyes A, DeAngelis MM (2020). Systemic Disease and Ocular Comorbidity Analysis of Geographically Isolated Federally Recognized American Indian Tribes of the Intermountain West. J Clin Med, 9(11).
- Hartnett ME (2020). Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor. Am J Ophthalmol, 218, 208-213.
- Thornburg CD, Erickson SW, Page GP, Clark EAS, DeAngelis MM, Hartnett ME, Goldstein RF, Dagle JM, Murray JC, Poindexter BB, Das A, Cotten CM (2020). Correction: Genetic predictors of severe intraventricular hemorrhage in extremely low-birthweight infants. J Perinatol.
- Levine ES, Custo Greig E, Mendona LSM, Gulati S, Despotovic IN, Alibhai AY, Moult E, Muakkassa N, Quaranta-El Maftouhi M, El Maftouhi A, Chakravarthy U, Fujimoto JG, Baumal CR, Witkin AJ, Duker JS, Hartnett ME, Waheed NK (2020). The long-term effects of anti-vascular endothelial growth factor therapy on the optical coherence tomography angiographic appearance of neovascularization in age-related macular degeneration. Int J Retina Vitreous, 6, 39.
- Bretz CA, Ramshekar A, Kunz E, Wang H, Hartnett ME (2020). Signaling Through the Erythropoietin Receptor Affects Angiogenesis in Retinovascular Disease. Invest Ophthalmol Vis Sci, 61(10), 23.
- Hamad AE, Moinuddin O, Blair MP, Schechet SA, Shapiro MJ, Quiram PA, Mammo DA, Berrocal AM, Prakhunhungsit S, Cernichiaro-Espinosa LA, Mukai S, Yonekawa Y, Ung C, Holz ER, Harper CA 3rd, Young RC, Besirli CG, Nagiel A, Lee TC, Gupta MP, Walsh MK, Khawly JA, Campbell JP, Kychenthal A, Nudleman ED, Robinson JE, Hartnett ME, Calvo CM, Chang EY (2019). Late-Onset Retinal Findings and Complications in Untreated Retinopathy of Prematurity. Ophthalmol Retina, 4(6), 602-612.
- Global Retinoblastoma Study Group, Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Caldern-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Catal-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Cska M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandio AC, Faranoush M, Fasina O, Fernndez DDPG, Fernndez-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, Garca Aldana D, Gassant PY, Geel JA, Ghassemi F, Girn AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, Gonzlez-Rodrguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gndz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivel TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, Lpez JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martn Begue N, Mason L, Mason JO 3rd, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Peer J, Pea A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, P (2020). Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol, 6(5), 685-695.
- Bretz CA, Simmons AB, Kunz E, Ramshekar A, Kennedy C, Cardenas I, Hartnett ME (2020). Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury. Am J Pathol, 190(3), 630-641.
- Wang H, Kunz E, Stoddard GJ, Hauswirth WW, Hartnett ME (2019). Optimal Inhibition of Choroidal Neovascularization by scAAV2 with VMD2 Promoter-driven Active Rap1a in the RPE. Sci Rep, 9(1), 15732.
- Mastey RR, Georgiou M, Langlo CS, Kalitzeos A, Patterson EJ, Kane T, Singh N, Vincent A, Moore AT, Tsang SH, Lin JH, Young MP, Hartnett ME, Hon E, Kohl S, Michaelides M, Carroll J (2019). Characterization of Retinal Structure in ATF6-Associated Achromatopsia. Invest Ophthalmol Vis Sci, 60(7), 2631-2640.
- Hartnett ME, Toth CA (2019). Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina, 50(4), 228-234.
- Jeng-Miller KW, Soomro T, Scott NL, Rao P, Marlow E, Chang EY, Ells A, Chau F, Nudleman E, Calvo CM, Patel N, Schwartz R, Cernichiaro-Espinosa LA, Montoya AG, Goldstein J, Harper CA 3rd, Baumal CR, Hartnett ME, Harbour JW, Besirli CG, Gupta MP, Chan RVP, Drenser KA, Capone A Jr, Murray TG, Mukai S, Trese MT, Berrocal AM, Wong SC, Yonekawa Y (2019). Longitudinal Examination of Fellow-Eye Vascular Anomalies in Coats' Disease With Widefield Fluorescein Angiography: A Multicenter Study. Ophthalmic Surg Lasers Imaging Retina, 50(4), 221-227.
- Mangalesh S, Bleicher ID, Chen X, Viehland C, LaRocca F, Izatt JA, Freedman SF, Hartnett ME, Toth CA (2019). Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 257(4), 677-688.
- Hartnett ME (2019). Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. Invest Ophthalmol Vis Sci, 60(5), 1286-1297.
- Han X, Kong J, Hartnett ME, Wang H (2019). Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci, 60(5), 1604-1613.
- Hicks PM, Melendez SAC, Vitale A, Self W, Hartnett ME, Bernstein P, Morgan DJ, Feehan M, Shakoor A, Kim I, Owen LA, DeAngelis MM (2019). Genetic Epidemiologic Analysis of Hypertensive Retinopathy in an Underrepresented and Rare Federally Recognized Native American Population of the Intermountain West. J Community Med Public Health, 3(1).
- Hansen ED, Hartnett ME (2019). A review of treatment for retinopathy of prematurity. Expert Rev Ophthalmol, 14(2), 73-87.
- Greene T, Hartnett ME (2018). Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. JAMA Ophthalmol, 137(1), 119.
- Yarishkin O, Phuong TTT, Bretz CA, Olsen KW, Baumann JM, Lakk M, Crandall A, Heurteaux C, Hartnett ME, Kriaj D (2018). TREK-1 channels regulate pressure sensitivity and calcium signaling in trabecular meshwork cells. J Gen Physiol, 150(12), 1660-1675.
- Simmons MA, Cheng AV, Becker S, Gerkin RD, Hartnett ME (2018). Automatic analysis of the retinal avascular area in the rat oxygen-induced retinopathy model. Mol Vis, 24, 767-777.
- Shulman JP, Hartnett ME (2018). Corrigendum: Pharmacotherapy and ROP: Going Back to the Basics. Asia Pac J Ophthalmol (Phila), 7(5), 365.
- Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856.
- Zayed MA, Uppal A, Hartnett ME (2010). New-onset maternal gestational hypertension and risk of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 51(10), 4983-8.
- Sleath B, Blalock SJ, Robin A, Hartnett ME, Covert D, DeVellis B, Giangiacomo A (2010). Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye (Lond), 24(4), 624-31.
- Budd SJ, Hartnett ME (2010). Increased Angiogenic Compounds during Persistent Avascular Retina in a Model of ROP. Arch Ophthalmol, 128(8), 1014-21.
- Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL (2009). Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol, 148(6), 895-901.e1.
- Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME (2009). Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res, 89(5), 718-27.
- Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature, 460(7252), 225-30.
- Byfield G, Budd S, Hartnett ME (2009). The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci, 50(7), 3360-5.
- Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V (2009). SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology, 116(4), 756-61.
- Ulmasov B, Bruno J, Gordon N, Hartnett ME, Edwards JC (2009). Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. Am J Pathol, 174(3), 1084-96.
- Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C (2009). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol, 127(3), 245-51.
- Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M (2009). SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology, 116(3), 504-12.
- Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd (2009). Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol, 127(2), 132-40.
- Reynolds R, Hartnett ME, Rosner B, Atkinson J, Giclas PC, Seddon JM (2009). Plasma Complement Components and Activation Fragments are Associated with Age-Related Macular Degeneration Genotypes and Phenotypes. Invest Ophthalmol Vis Sci.
- Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H (2008). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology, 115(8), 1366-71, 1371.e1.
- Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008). Vascular endothelial growth factor in eye disease. Prog Retin Eye Res, 27(4), 331-71.
- Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL (2008). Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci, 49(7), 3107-14.
- Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H (2008). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina, 28(7), 919-30.
- Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU (2008). Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci, 49(5), 1745-52.
- Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK (2008). Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol, 145(5), 894-901.
- Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME (2008). Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci, 49(4), 1591-8.
- Hartnett ME, Board RJ, Houghton O (2008). Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. Retina, 28(3 Suppl), S69-74.
- Vinekar A, Trese MT, Capone A Jr (2008). Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol, 145(3), 548-555.
- Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME (2008). Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis, 14, 345-57.
- Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H (2008). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina, 28(1), 36-40.
- Diabetic Retinopathy Clinical Research Network (2008). A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 115, 1445-1456.
- Writing Committee for The Photographic Screening for Retinopathy of Prematurity Study Photo- ROP (2008). Primary Outcomes Ophthalmology. Retina, 28, S47-S54.
- Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, and Sinclair E, for the Studies of Ocular Complications of AIDS Research Group (2008). Poor predictive value of cytomegalovirus (CMV)-Specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis, 46, 458-466.
- Zayed MA, Yuan W, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, Hartnett ME, Faber JE, Parise LV (2007). CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circ Res, 101(11), 1185-93.
- Bhavsar AR, Ip MS, Glassman AR (2007). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol, 144(3), 454-6.
- Diabetic Retinopathy Clinical Research Network (2007). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology, 114(8), 1520-5.
- Saito Y, Geisen P, Uppal A, Hartnett ME (2007). Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis, 13, 840-53.
- Peterson LJ, Wittchen ES, Geisen P, Burridge K, Hartnett ME (2007). Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. Exp Eye Res, 84(4), 737-44.
- Diabetic Retinopathy Clinical Research Network (2007). Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol, 125(4), 469-80.
- Diabetic Retinopathy Clinical Research Network (2007). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology, 114(3), 525-36.
- Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch VL (2007). Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood, 109(4), 1345-52.
- Steering Committee of Diabetic Retinopathy Clinical Research Network (2007). A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology, 114, 1860-1867.
- Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular diagnoses at enrollment. Ophthalmology, 114, 780-786.
- Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 2. Ocular examination results at enrollment. Ophthalmology, 114, 787-793.
- Diabetic Retinopathy Clinical Research Network (2006). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol, 124(12), 1701-7.
- Hartnett ME, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ, McColm JR (2006). Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci, 47(11), 4975-82.
- Geisen P, McColm JR, King BM, Hartnett ME (2006). Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr Eye Res, 31(9), 739-48.
- Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese MT (2006). The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. Retina, 26(7 Suppl), S4-10.
- Hartnett ME, McColm JR (2006). Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. Retina, 26(7 Suppl), S24-31.
- McColm JR, Geisen P, Peterson LJ, Hartnett ME (2006). Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. Exp Eye Res, 83(2), 438-46.
- Escaravage GK Jr, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski CM (2006). Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg, 32(5), 803-11.
- Geisen P, McColm JR, Hartnett ME (2006). Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res, 82(4), 608-19.
- PKC-DRS2 Group PI for LSU site (2006). Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113, 2221-2230.
- Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL, for the Studies of Ocular Complications of AIDS Research Group (2006). Causes of Visual Acuity Loss Among Patients with AIDS and Cytomegalovirus in the Era of Highly Active Antiretroviral Therapy. Ophthalmology, 113, 1441-1445.
- Kempen JH, Min Y-I, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2006). Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology, 113, 684-694.
- Hartnett ME, Key IJ, Loyacano NM, Horswell RL, Desalvo KB (2005). Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol, 123(3), 387-91.
- Hartnett ME, Maguluri S, Thompson HW, McColm JR (2004). Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina, 24(5), 753-7.
- McColm JR, Geisen P, Hartnett ME (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis, 10, 512-20.
- Van Cott EM, Laposata M, Hartnett ME (2004). Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis, 15(5), 393-7.
- Hartnett ME, McColm JR (2004). Retinal features predictive of progressive stage 4 retinopathy of prematurity. Retina, 24(2), 237-41.
- Jacobson MA, Maecker HT, Orr PL, DAmico R, Van Natta M, Li XD Pollard RB, Bredt BM for the Adult AIDS Clinical Trials Group and the Studies of Ocular Complications of AIDS Research Group (2004). Results of a CMV-specific CD8+/IFNy+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in AIDS patients with CMV retinitis. J Infect Dis, 189, 1362-1373.
- Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK for the Studies of Ocular Complications of AIDS Research Group (2004). Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology, 111, 2232-2239.
- Marshall BC, Jacobson MA, Adler SP in collaboration with the Studies of Ocular Complications of AIDS Research Group (2004). Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral Immunol, 17, 101-108.
- Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, DAmore PA (2003). Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp Eye Res, 77(5), 593-9.
- Maguluri S, Hartnett ME (2003). Radial choroidal ruptures in sclopetaria. J Am Coll Surg, 197(4), 689-90.
- Hartnett ME, Rodier DW, McColm JR, Thompson HW (2003). Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity. Arch Ophthalmol, 121(7), 991-6.
- Hartnett ME (2003). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina, 23(3), 322-9.
- Hartnett ME, Laposata M, Van Cott E (2003). Antiphospholipid antibody syndrome in a six-year-old female patient. Am J Ophthalmol, 135(4), 542-4.
- Kempen JH, Martin BK, Wu A, Barron B, Thorne JE, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2003). The effect of cytomegalovirus retinitis on the quality of life of patients with acquired immune deficiency syndrome in the era of highly active anti-retroviral therapy. Ophthalmology, 110, 987-995.
- Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D for the Studies of Ocular Complications of AIDS Research Group (2003). Visual loss in patients with cytomegalovirus retinitis and AIDS before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol, 121(1), 99-107.
- Miura M, Elsner AE, Beausencourt E, Kunze C, Hartnett ME, Lashkari K, Trempe CL (2002). Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration. Retina, 22(3), 300-8.
- Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D (2000). Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care, 23(2), 234-40.
- Beausencourt E, Remky A, Elsner AE, Hartnett ME, Trempe CL (2000). Infrared scanning laser tomography of macular cysts. Ophthalmology, 107(2), 375-85.
- The STOP-ROP Multicenter Study Group (2000). Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A randomized, controlled trial. I: Primary Outcomes. Pediatrics, 105, 295-310.
- Andrews AP, Hartnett ME, Hirose T (1999). Surgical advances in retinopathy of prematurity. Int Ophthalmol Clin, 39(1), 275-90.
- Sheindlin JA, Hirose T, Hartnett ME (1999). Ophthalmic endoscopy: applications in intraocular surgery. Int Ophthalmol Clin, 39(1), 237-47.
- Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner AE (1999). Infrared imaging of cystoid macular edema. Graefes Arch Clin Exp Ophthalmol, 237(11), 897-901.
- Hartnett ME, Garcia CM, DAmore PA (1999). Release of bFGF, an endothelial cell survival factor, by osmotic shock. Invest Ophthalmol Vis Sci, 40(12), 2945-51.
- Kunze C, Elsner AE, Beausencourt E, Moraes L, Hartnett ME, Trempe CL (1999). Spatial extent of pigment epithelial detachments in age-related macular degeneration. Ophthalmology, 106(9), 1830-40.
- Hartnett ME, Hirose T (1998). Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. Retina, 18(2), 125-9.
- Armstrong D, Ueda T, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, Hartnett M, Buch P, Dandona P, Sasisekharan R, Dorey CK (1998). Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis, 2(1), 93-104.
- Beausencourt E, Elsner AE, Hartnett ME, Trempe CL (1997). Quantitative analysis of macular holes with scanning laser tomography. Ophthalmology, 104(12), 2018-29.
- Armstrong D, Ueda To, Ueda Ta, Browne R, Al-Jada A, Spengler R, Chou R, Fukuda S, Buch P, Dandona P, Hartnett ME, Sasisekharan R, Dorey KC (1997). Expression of TNF-alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. Angiogenesis, 2, 174-84.
- Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996). Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology, 103(12), 2042-53.
- Steidl SM, Hirose T, Sang D, Hartnett ME (1996). Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report. Ophthalmologica, 210(6), 336-40.
- Hartnett ME, Elsner AE (1996). Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. Ophthalmology, 103(1), 58-71.
- Steidl S, Hirose T, Hartnett ME (1995). Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma. Int Ophthalmol Clin, 35(1), 175-80.
- Hartnett ME, Pruett RC, DaSilva KC, Burkart PT (1994). Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol, 118(3), 397-8.
- Hartnett ME, Katsumi O, Hirose T, Richardson TM, Walton DS (1994). Improved visual function in retinopathy of prematurity after lowering high intraocular pressure. Am J Ophthalmol, 117(1), 113-5.
- Hartnett ME, Coles WH (1993). Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration. Am J Ophthalmol, 116(2), 250-1.
- Hartnett ME, Gilbert MM, Hirose T, Richardson TM, Katsumi O (1993). Glaucoma as a cause of poor vision in severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 231(8), 433-8.
- Hartnett ME, Hirose T, Richardson TM, Garsd A, Gilbert MM, Krug J Jr (1992). Intraocular pressure determination in infants with severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 230(5), 406-10.
- Hartnett ME, Weiter JJ, Garsd A, Jalkh AE (1992). Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol, 230(1), 11-9.
- Hartnett ME, Gilbert MM, Richardson TM, Krug JH Jr, Hirose T (1990). Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology, 97(1), 122-30.
- Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH (1987). Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol, 104(5), 476-80.
- Mangan KF, Hartnett ME, Matis SA, Winkelstein A, Abo T (1984). Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood, 63(2), 260-9.
- Krohel GB, Tobin DR, Hartnett ME, Barrows NA (1982). Divergence paralysis. Am J Ophthalmol, 94(4), 506-10.
Edited Book
- Hartnett ME, ed-in-chief (Eds.) (2005). Pediatric Retina, 1st Edition. Philadelphia, PA: Lippincott Williams & Wilkins.
- Steidl S, Hartnett ME (Eds.) (2003). Clinical Pathways in Vitreoretinal Disease. New York, NY: Thieme Publishers.
- Schepens CL, Hartnett ME, Hirose T (Eds.) (2000). Schepens’ Retinal Detachment and Allied Diseases. (2nd edition). Boston, MA: Butterworth-Heinemann.